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ABSTRACT 
Semelil (ANGIPARS™), a novel herbal-based compound containing extract of Melilotus 
officinalis, was formulated for treatment of chronic wounds, especially diabetic foot ulcer. 
The purpose of this study was to investigate safety and toxicity effects of intramuscular 
administration of Semelil in dogs.  
Preliminary one-month study with Semelil was performed on 8 male and female dogs 
divided into 2 groups, test and control, four animals each. Semelil was administered 
intramuscularlyat a dose of 0.07 ml/kg body wt. once a day to the animals of the test group, 
while the control group received sterile saline. During experiments, general state of the 
animals including the dynamics of body weight changes, appetite, motor activity and 
behavior, hair condition, ECG parameters, rectal temperature of animals and data of 
hematological and biochemical tests were monitored for signs of toxicity and side-effects. 
Finally, morphology and histology analyses were performed using standard methods. 
No adverse health or toxicity effects were observed through the course of the study. No 
damaging consequences of Semelil injections on the functional state of main organs of the 
experimental animals were found. This observation gave a good evidence of a favorable 
safety profile compatible with potential therapeutic use of Semelil. 
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INTRODUCTION 
Diabetes mellitus is one of the most important 
causes of disability and death in the world (1-3). 
Serious long-term complications including 
microvascular dysfunctions cause poor healing 
wounds, particularly in the feet and legs which 
result in amputation. Diabetes can dull the 
sensitivity of nerves called peripheral neuropathy 
and thus patients might not become aware of a 
sore spot. The ulcer can become infected and the 
area may not readily heal because of poor blood 
circulation. Proper treatment can help ulcers heal 
and prevent new ones from developing (4-6). 
Therefore, appropriate interventions for wound 
care for reducing amputation rates are essential. 
Herbal extracts are among the medications which 
can be used easily on wounds. There are several 
evidences about the putative clinical usefulness of 
Melilotus sp. with both internal and external 
administration routes for ameliorating skin aging, 
micro-circulation improvement, and anti-
inflammatory effects. Its combination with 
Ginkgo biloba has been helpful for treatment of 
thrombosis, circulation and sub-acute 
degenerative problems (7-9).  
Prior to the initiation of human clinical trials of 
novel drugs, the safety of their application is to be 
proved. Generally this is accomplished by the 
implementation of general preclinical toxicity 
experiments to uncover potential poisonous 
effects of any drug in animals. The aim of the 
present study was to evaluate the animal safety of 
Semelil (ANGIPARS™) as a new 
phytotherapeutic candidate for wound healing.  
 
MATERIALS AND METHODS 
Semelil herbal extract (ANGIPARS™) was 
prepared and delivered by ParsRoos Co. (Tehran, 
Iran).  
A set of reagents of the Labsystems (Finland) was 
applied for measurement the glucose level. Total 
protein, creatinine, urea, total bilirubin, the 
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activities of lactate dehydrogenase and alkaline 
phosphatase were determined by a set of reagents 
of Diakom-Sinteco, Co. (Russia). Triglyceride 
and cholesterol levels were measured by a set of 
reagents from DiaSys Co. An automatic cell 
counter Pikoskel (Hungary) was used for counting 
blood elements. The activity of alanine 
aminoteransferase was determined using a set of 
reagents of Corway (Poland). A biochemical 
semiautomatic analyzer FP-901 Labsystems 
(Finland) was utilized for assessment of other 
biochemical parameters and enzyme activities. 
The ECG examination of dogs was performed by 
a Biograph device (USA).  
 
Drug solution preparation 
The Semelil was freshly diluted in sterile solution 
of sodium chloride 0.9% at 1:10 ratio and then 
was administered to animals.  
 
Animals 
Healthy young dogs, 12-14.5 kg (4 males and 4 
females), which had been acclimated to laboratory 
conditions and had not been subjected to previous 
experimental procedures, were enrolled. 
Conventional laboratory diet was used with an 
unlimited supply of drinking water. Artificial 
lighting, with the sequence being 12 hours light, 
12 hours dark was used (10-12). Animals were 
handled in accord with the laboratory animal 
welfare guidelines.  
 
Sub-chronic toxicity evaluation  
The protocol of the study was approved by the 
Institute Animals Ethics Committee. Sub-chronic 
toxicity tests were performed on 8 male and 
female dogs divided into 2 groups of test and 
control, 4 animals in each, and Semelil was 
administered at a dose of 0.07 ml/kg once a day 
intramuscularly to the test group for a period of 
one month. The control group received sterile 
saline solution.  
During the experiments, general state of the 
animals including the dynamics of body weight 
changes, appetite, motor activity, hair condition, 
the ECG parameters, rectal temperature and 
behavior of the animals were recorded (13,14). At 
the baseline of the study and one month after the 
first administration, a blood sample (2-2.5 ml) 
was taken from subcutaneous vein of each animal 
and the hematological, and biochemical analyses 
were conducted.  
 
Gross necropsy 
At the end of the sub-chronic experiments, the 
animals were euthanized by over-dosage of 
thiopental with pre-medication of droperidol in 
order to conduct histopathological examination of 
the internal organs and tissues. All animals in the 
study were subjected to a full, detailed gross 
necropsy which included careful examination of 
the external surface of the body, all orifices, and 
the cranial, thoracic and abdominal cavities and 
their contents. The tissues were preserved in the 
appropriate fixation medium for intended 
subsequent histopathological examination.  
 
Statistical Analyses 
All determinations were subjected to calculation 
of mean and SD for the outcome variable. 
Statistical analyses were performed by using 
SPSS software, v. 11.5. The probability levels of 
significance were based on non-parametric tests. 
Statistically significance level was set at p<0.05.  
 
RESULTS AND DISCUSSION 
Sub-chronic toxicity evaluation: The data for all 
tests showed that I.M. injection of Semelil at the 
dose of 0.07 ml/kg had no effects on the general 
state and behavior of the animals. We did not 
detect any significant changes in hematological 
(Tables 1 and 2) and biochemical parameters 
including total serum proteins, serum bilirubin, 
serum glucose, triglycerides, cholesterol, blood 
urea and creatinine (Table 3), in test group 
compared to control group after 1 month (p>0.05). 
The ECG data (Table 4) and activities of hepatic 
enzymes (Table 5) of test and control groups did 
not show any difference and corresponded to the 
physiological range of these parameters. The body 
weight and rectal temperature of animals in 
experimental group, during all period of study 
were not significantly different (p>0.05) from that 
of control animals (Table 6).  
Although small animal, like mice and rats, are 
most frequently used animals in preclinical drug 
developments, phenotypic characterization of the 
behavior, physiology and biochemistry tests on 
rodent models have some limitations. For this 
reason, usage of bigger animals, like dogs, is very 
important in advanced preclinical studies. 
 
Pathomorphological examination of animals 
Microscopic data together with the data of 
macroscopic evaluation of the animals’ organ 
showed that both test and control groups were 
practically healthy. According to the data of 
histological examination, no toxic or allergic 
effects of Semelil were detected in the test group. 
No pathological changes of the internal organs 
and no local irritating effects of the drug 
preparation were observed in the test group during 
the study period. 
Our experiments showed that Semelil 
administrated I.M. in dogs has a low-toxicity. We 
did not observe any significant change in total 
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Table 1. Hematological parameters in dogs (1-month study) after I.M. injection of Semelil at the dose of 0.07 ml/kg. 
The control group received 0.9% sodium chloride. 
Semelil (0.07 ml/kg) Control Observation period 
Erythrocytes, 1012 /l 
6.8 ± 0.6 7.2 ± 0.4 Before introduction 
7.4 ± 0.4 6.9 ± 0.4 1 month after introduction 
Leukocytes, 109 /l 
9.9 ± 0.6 9.4 ± 0.6 Before introduction 
9.6 ± 0.4 9.8 ± 0.4 1 month after introduction 
Thrombocytes, 109 /l 
413 ± 72 386 ± 46 Before introduction 
388 ± 58 396 ± 58 1 month after introduction 
Hemoglobin, g /l 
108 ± 6 106 ± 6 Before introduction 
109 ± 6 108 ± 8 1 month after introduction 




Table 2. The percentage of leukocytic formula of the blood of dogs (after 1 month study), I.M. injection of Semelil at 
the dose of 0.07 ml/kg. The control group received 0.9% sodium chloride. 
Neutrophils 




Eosinophils Basophils Animal groups 
4.6 ± 0.6 32.2 ± 3.2 61.9 ± 4.8 4.2 ± 0.6 5.5 ± 1.0 0.6 ± 0.4 Control 
4.7 ± 1.0 25.2 ± 3.6 59.2 ± 6.4 4.6 ± 0.6 5.8 ± 0.8 0.5 ± 0.4 Semelil 0.07ml/kg 




Table 3. Biochemical parameters in dogs (1-month study) after I.M. injection of Semelil at the dose of 0.07 ml/kg. The 
control group received 0.9% sodium chloride. 
Semelil (0.07 ml/kg) Control Observation periods 
Total serum protein (g/l) 
70.06 ± 4.1 69.12 ± 11.5 Before introduction 
64.65 ± 5.2 68.81 ± 12.1 1 month after introduction 
Total bilirubin µmol /l 
7.59 ± 0.7 6.88 ± 0.65 Before introduction 
6.87 ± 2.75 7.02 ± 0.55 1 month after introduction 
Glucose (mmol/l) 
6.02 ± 0.55 6.26 ± 0.8 Before introduction 
6.42 ± 0.56 6.33 ± 0.44 1 month after introduction 
Urea (mmol /l) 
8.78 ± 0.56 9.69 ± 0.9 Before introduction 
9.35 ± 0.22 9.53 ± 0.86 1 month after introduction 
Creatinine (µmol /l) 
54.86 ± 8.34 59.62 ± 9.86 Before introduction 
65.43 ± 14.54 61.32 ± 9.86 1 month after introduction 
Total cholesterol (mmol /l) 
2.59 ± 0.44 2.39 ± 0.24 Before introduction 
2.23 ± 0.58 2.67 ± 0.52 1 month after introduction 
Triglyceride (mmol /l) 
0.65 ± 0.14 0.79 ± 0.12 Before introduction 
0.43 ± 0.1 0.74 ± 0.12 1 month after introduction 
Data are means ± standard deviation, All significance levels between groups were p>0.05. 
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Table 4.  ECG parameters  in dogs (1-month study) after  I.M. injection of Semelil at the dose of 0.07 ml/kg. The 
control group received 0.9% sodium chloride. 




 (0.07 ml/kg) 
Control 
ECG parameters 
462 ± 44 466 ± 64 458 ± 70 467 ± 76 R-R, msec 
89 ± 32 85 ± 42 89 ± 32 86 ± 24 P-Q, msec 
139 ± 30 138 ± 30 146 ± 36 139 ± 38 Q-T, msec 
39 ± 12 39 ± 8 39 ± 6 40 ± 12 QRS, msec 
0.4 ± 0.2 0.3 ± 0.2 0.3 ± 0.2 0.4 ± 0.4 ST, msec 
194 ± 46 186 ± 44 192± 56 189 ± 38 TP, msec 
0.28 ± 0.08 0.26 ± 0.08 0.29 ± 0.1 0.30 ± 0.06 P, msec 
1.38 ± 0.46 1.42 ± 0.44 1.39 ± 0.48 1.38 ± 0.24 R, msec 
0.28 ± 0.1 0.29 ± 0.12 0.32 ± 0.12 0.30 ± 0.12 T, msec 
146 ± 24 138 ± 30 145 ± 30 139 ± 30 Heart rate/min 
Data are means ± standard deviation, All significance levels between groups were p>0.05. 
 
Table 5. Hepatic enzyme activity in dogs (1-month study) after I.M. injection of Semelil at the dose of 0.07 ml/kg. The 
control group received 0.9% sodium chloride. 
Semelil 
(0.07 ml/kg) Control Observation periods 
Alkaline phosphatase unit /l 
204.62 ± 37 199.54 ± 20.5 Before introduction 
194.28 ± 36 189.17 ± 25 1 month after introduction 
Lactate dehydrogenase unit /l 
182.43 ± 37.3 163.24 ± 22.8 Before introduction 
172.33± 35.7 164.28 ± 21.5 1 month after introduction 
Aspartate aminotransferase unit /l 
49.77± 13.7 40.22 ± 6.4 Before introduction 
34.33± 4.8 39.70 ± 7.6 1 month after introduction 
Alanine aminotransferase unit /l 
64.99 ± 8.3 59.22 ± 6.7 Before introduction 
60.05 ± 4.9 61.37 ± 7.1 1 month after introduction 
Data are means ± standard deviation; All significance levels between groups were p>0.05. 
 
Table 6. The dynamics of body weight changes and rectal temperature in dogs (1-month study) after I.M. injection of 
Semelil at the dose of 0.07 ml/kg. The control group received 0.9% sodium chloride. 
Semelil 
(0.07 ml/kg) Control Observation periods 
Body weight, % initial weight 
105.4 ± 5.2 103.6± 5.6 After 1 month 
Rectal temperature, °C 
38.8 ± 0.4 38.8 ± 0.2 Before introduction 
38.7 ± 0.2 38.6 ± 0.4 After 1 month 
Data are means ± standard deviation, All significance levels between groups were p>0.05. 
 
hematological and biochemical parameters in test 
groups compared to control group. The data 
indicated the stability of protein-productive 
function of liver, hepatic enzyme activity, 
carbohydrate metabolism, pancreas function, lipid 
metabolism and excretory function of kidneys 
during the study period.  
 
CONCLUSIONS 
The present study is an evidence of good 
tolerance and safety of Semelil (ANGIPARS™) 
and without undesirable effects on the functional 
state of the main organs of these animals after 
one-month treatment. Taking these results into 
account, Semelil could be recommended for 
clinical trials in humans. Since antioxidants are 
believed to be useful in the management of 
diabetes and its complications (15) antioxidant 
potential of Samelil should be focus of the next 
step of trials.  
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